1. Aghajanina, G. K., and Bing, O. H., 1964, Persistence of lysergic acid diethylamide in the plasma of human subjects, Clin. Pharmacol. Ther. 5:611–614.
2. Anderson, W. H., and O’Malley, J. E., 1972, Trifluoperazine for the “trailing” phenomenon, J.A.M.A. 220:1244.
3. Angrist, B., Rotrosen, J., and Gershon, S., 1974, Assessment of tolerance to the hallucinogenic effects of DOM, Psychopharmacologia 36:203–207.
4. Aptekar, R. G., and Mitchinson, M. J., 1970, Retroperitoneal fibrosis in two patients previously exposed to LSD. California Med. 113:77.
5. Aronson, H., Silverstein, A. B., and Klee, G. D., 1959, Influence of lysergic acid diethylamide (LSD-25) on subjective time. Arch. Gen. Psychiat. 1:469.